<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">Aside from the above positive results, we also showed that ritonavir (
 <bold>9</bold>) and lopinavir (
 <bold>10</bold>) failed to inhibit the SARS-CoV-2 M
 <sup>pro</sup> (IC
 <sub>50</sub> &gt; 20 µM, Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>), which might explain why they lack efficacy in clinical trials for COVID-19.
 <sup>
  <xref ref-type="bibr" rid="CR31">31</xref>
 </sup> Camostat (
 <bold>39</bold>) was recently proposed to inhibit SARS-CoV-2 entry through inhibiting the host TMPRSS2, a host serine protease that is important for viral S protein priming.
 <sup>
  <xref ref-type="bibr" rid="CR37">37</xref>
 </sup> In our study, we found that camostat (
 <bold>39</bold>) has no inhibition against the SARS-CoV-2 M
 <sup>pro</sup> (IC
 <sub>50</sub> &gt; 20 µM).
</p>
